Trial Profile

Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Catequentinib (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms CSOAIMTOAN

Most Recent Events

05 Jul 2024 Results (n=23) of pooled analysis of two studies ALTER-L014 and ALTER-L011 assessing efficacy and safety of maintenance therapy with anlotinib after platinum-based induction chemotherapy for patients with advanced NSCLC, published in the Medicine.
14 Sep 2021 Results presented at the 2021 World Conference on Lung Cancer
20 Oct 2019 Planned primary completion date changed from 31 Dec 2019 to 31 Dec 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com